TLL-018 is a novel, highly potent, and selective TYK2/JAK1 inhibitor.

The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis.

 This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA).

TLL-018 is a novel, highly potent, and selective TYK2/JAK1 inhibitor. TYK2 and JAK1 are the key regulators of pro-inflammatory cytokines. 

"We are elated to have enrolled our first patient in the TLL018-205 trial. This is a significant milestone for the trial and a noteworthy achievement for our clinical operations team. The investigators on this trial are exceptional and have done a remarkable job pre-screening and using modern patient recruitment tactics," says Joshua Ondatje, VP of Clinical Operations at Vial, in a news release. Vial is a CRO providing next-generation clinical trial management services. 

"We are pleased to hear that Vial has enrolled the first patient for the study. We hope that with the help of Vial's tech-enabled clinical management services, we can complete this trial expeditiously and with high quality," adds Vance Oertel, VP of Clinical Operations at Highlightll Pharmaceutical, USA.